KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ionis Pharmaceuticals (IONS) over the last 10 years, with Q3 2025 value amounting to $24.8 million.

  • Ionis Pharmaceuticals' Other Accumulated Expenses rose 1243.94% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 1243.94%. This contributed to the annual value of $19.5 million for FY2024, which is 3424.56% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Other Accumulated Expenses is $24.8 million, which was up 1243.94% from $22.8 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $29.6 million during Q4 2023, with a 5-year trough of $9.6 million in Q1 2023.
  • For the 5-year period, Ionis Pharmaceuticals' Other Accumulated Expenses averaged around $17.8 million, with its median value being $18.0 million (2024).
  • In the last 5 years, Ionis Pharmaceuticals' Other Accumulated Expenses tumbled by 6009.53% in 2021 and then soared by 14264.63% in 2023.
  • Ionis Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $12.3 million in 2021, then fell by 0.95% to $12.2 million in 2022, then surged by 142.65% to $29.6 million in 2023, then plummeted by 34.25% to $19.5 million in 2024, then grew by 27.44% to $24.8 million in 2025.
  • Its Other Accumulated Expenses was $24.8 million in Q3 2025, compared to $22.8 million in Q2 2025 and $22.3 million in Q1 2025.